Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) has issued an announcement.
Algorae Pharmaceuticals has applied to the ASX for quotation of 89,350,001 new fully paid ordinary shares, issued on 2 April 2026 under its existing capital management framework. The move significantly expands the company’s quoted share base, potentially enhancing liquidity in its stock and providing additional capital flexibility for future operational or strategic initiatives.
The application, lodged as a new announcement under the ASX Appendix 2A process, formalizes the admission of these shares to trading under the ticker 1AI. While the release does not specify the purpose or use of funds linked to this issuance, the scale of the new securities indicates a material capital event that may affect ownership structure and market perception of Algorae Pharmaceuticals.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australia-based biotechnology company listed on the ASX under the code 1AI. The company operates in the pharmaceuticals sector, focusing on developing and commercializing drug products, though the specific therapeutic areas or lead programs are not detailed in this announcement.
YTD Price Performance: 14.29%
Average Trading Volume: 1,506,343
Technical Sentiment Signal: Hold
Current Market Cap: A$28.18M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.